CUTANEOUS SQUAMOUS CELL CARCINOMA TREATMENT MARKET ANALYSIS

Cutaneous Squamous Cell Carcinoma Treatment Market, by Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Electrodessication or Curettage), Non-surgical (Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, and Systemic Chemotherapy)), by Application (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020
Code : CMI4280
Pages :195
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Increasing incidence of cutaneous squamous-cell carcinoma is expected to boost the market growth. For instance, according to the Journal of the European Academy of Dermatology and Venereology, an article published in January 2019, reports that in the period 2007-2015, 76,474 people newly diagnosed with squamous-cell carcinoma (SCC) were registered in North Rhine?Westphalia (NRW), with an age?standardized incidence in 2015 of 54 in men, double the rate of 26 in women.

Major players in the market are focused on drug development for cutaneous squamous cell carcinoma treatment, which is expected to boost the market growth over the forecast period. for instance, in May 2020, Regeneron Pharmaceuticals, Inc., and Sanofi A.S., collaboratively initiated the clinical trial and announced the longer-term results for Libtayo (cemiplimab-rwlc), PD-1 inhibitor from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (cSCC). The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) annual meeting.